Payment overview · 2025
General Payments
$183.40
8 reported records · 7 companies
Healthcare provider profile · identity verified
Carl Dean Mccurdy, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JASPER, GA · NPI 1780679134
Verified facts
What the public records show
CMS Open Payments records show Carl Dean Mccurdy, M.D. received $183.40 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.40 | 25.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.81 | 19.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.91 | 14.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.71 | 10.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.70 | 10.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.69 | 10.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.18 | 9.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.40 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.40 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.81 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 554 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 525 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 144 |
| Losartan Potassium | Losartan Potassium | 472 | 133 |
| Lisinopril | Lisinopril | 425 | 116 |
| Omeprazole | Omeprazole | 389 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 368 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 294 | 78 |
| Gabapentin | Gabapentin | 251 | 62 |
| Metformin Hcl | Metformin Hcl | 238 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 69 |
| Alprazolam | Alprazolam | 215 | 57 |
| Simvastatin | Simvastatin | 208 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 58 |
| Carvedilol | Carvedilol | 173 | 44 |
| Paroxetine Hcl | Paroxetine Hcl | 171 | 46 |
| Furosemide | Furosemide | 157 | 50 |
| Sertraline Hcl | Sertraline Hcl | 148 | 45 |
| Trazodone Hcl | Trazodone Hcl | 146 | 41 |
| Allopurinol | Allopurinol | 143 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 41 |
| Eliquis | Apixaban | 135 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 39 |
| Valsartan | Valsartan | 127 | 27 |
| Potassium Chloride | Potassium Chloride | 126 | 31 |
| Finasteride | Finasteride | 125 | 31 |
| Ozempic | Semaglutide | 122 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 33 |
| Metformin Hcl Er | Metformin Hcl | 103 | 31 |
| Meloxicam | Meloxicam | 99 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 29 |
| Famotidine | Famotidine | 96 | 28 |
| Lorazepam | Lorazepam | 94 | 25 |
| Memantine Hcl | Memantine Hcl | 94 | 24 |
| Glipizide Er | Glipizide | 85 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 84 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 32 |
| Montelukast Sodium | Montelukast Sodium | 82 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 20 |
| Donepezil Hcl | Donepezil Hcl | 75 | 14 |
| Risperidone | Risperidone | 74 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 22 |
| Tramadol Hcl | Tramadol Hcl | 66 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 14 |
| Prednisone | Prednisone | 58 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 19 |
| Clonazepam | Clonazepam | 56 | 12 |
| Januvia | Sitagliptin Phosphate | 56 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 18 |
| Glimepiride | Glimepiride | 54 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 11 |
| Spironolactone | Spironolactone | 51 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 15 |
| Ezetimibe | Ezetimibe | 48 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Glipizide | Glipizide | 43 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 26 |
| Mupirocin | Mupirocin | 35 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 26 |
| Temazepam | Temazepam | 35 | 11 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 11 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | 13 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 12 |
| Amoxicillin | Amoxicillin | 28 | 23 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | 12 |
| Atenolol | Atenolol | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 11 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | 11 |
| Ondansetron Odt | Ondansetron | 22 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.40 · 8 records | Novo Nordisk Inc | ABRYSVO, AREXVY, COMIRNATY, Dexcom G6 Transmitter, JARDIANCE, Korlym, Ozempic, PREVNAR 20, QULIPTA, SHINGRIX, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error